dipyridamole has been researched along with malondialdehyde in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (52.63) | 18.7374 |
| 1990's | 7 (36.84) | 18.2507 |
| 2000's | 1 (5.26) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Best, LC; Martin, TJ; McGuire, MB; Preston, FE; Russell, RG; Segal, DS | 1 |
| Best, LC; Holland, TK; Jones, PB; Martin, TJ; McGuire, MB; Preston, FE; Russell, RG; Segal, DS | 1 |
| Carrasco, T; de la Cruz, JP; Ortega, G; Sanchez de la Cuesta, F | 1 |
| De la Cruz, JP; Sanchez de la Cuesta, F | 1 |
| Brickl, R; Eisert, WG; Müller, TH; Nehmiz, G; Su, CA; Weisenberger, H | 1 |
| Aguilar Muñoz, A; de la Cruz Cortés, JP; de Pablo Molina, J; García Arnés, J; Martos Crespo, F; Sánchez de la Cuesta, F | 1 |
| Berrettini, M; Costantini, V; Grasselli, S; Nenci, GG; Todisco, T | 1 |
| Bertoli, L; Colli, S; Lo Cicero, S; Maderna, P; Mantero, O; Tremoli, E | 1 |
| Bottecchia, D; Doni, MG; Fantin, G | 1 |
| Bayer, BL; Blass, KE; Block, HU; Förster, W; Giessler, C; Mentz, P; Pönicke, K | 1 |
| Bertoli, L; Colli, S; Maderna, P; Mantero, O; Merlini, R; Sirtori, CR; Tremoli, E | 1 |
| Bizzi, B; Leone, G; Traisci, G; Valori, VM | 1 |
| Chong, BH; Grace, CS; Rozenberg, MC | 1 |
| Ferro, D; Iuliano, L; Pedersen, JZ; Rotilio, G; Violi, F | 1 |
| de la Cruz, JP; García-Campos, J; Mérida, F; Moreno, A; Sánchez de la Cuesta, F | 1 |
| Benítez, A; De la Cruz, JP; Gonzalez-Correa, JA; Olveira, C; Sánchez de la Cuesta, F | 1 |
| Higuchi, C; Nakano, Y; Nihei, H; Nishimura, H; Omata, M; Sanaka, T; Shinobe, M; Sugino, N | 1 |
| Boonyen, M; Futrakul, N; Futrakul, P; Patumraj, S; Siriviriyakul, P; Tosukhowong, P | 1 |
| Alyasiry, E; Hadi, N; Janabi, A | 1 |
2 trial(s) available for dipyridamole and malondialdehyde
| Article | Year |
|---|---|
Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo.
Topics: Adult; Aspirin; Blood Platelets; Dipyridamole; Double-Blind Method; Drug Interactions; Endothelium, Vascular; Female; Humans; In Vitro Techniques; Male; Malondialdehyde; Middle Aged; Platelet Aggregation; Thrombosis | 1990 |
[Effect of dipyridamole (225 mg/day) and acetylsalicylic acid (150 mg/day) on various platelet parameters in non-complicated diabetes mellitus].
Topics: Aspirin; Blood Platelets; Diabetes Mellitus, Type 1; Dipyridamole; Humans; Malondialdehyde; Platelet Aggregation | 1986 |
17 other study(ies) available for dipyridamole and malondialdehyde
| Article | Year |
|---|---|
Dipyridamole and platelet function.
Topics: Anticoagulants; Cyclic AMP; Dipyridamole; Humans; In Vitro Techniques; Malondialdehyde; Platelet Aggregation; Thromboxane B2 | 1978 |
Mode of action of dipyridamole on human platelets.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; Adenosine Diphosphate; Adenylyl Cyclases; Blood Platelets; Cell Membrane; Cyclic AMP; Cyclic GMP; Dipyridamole; Epinephrine; Epoprostenol; Humans; Malondialdehyde; Platelet Aggregation; Thromboxane B2; Time Factors | 1979 |
Inhibition of ferrous-induced lipid peroxidation by pyrimido-pyrimidine derivatives in human liver membranes.
Topics: Animals; Ascorbic Acid; Cardiotonic Agents; Cell Membrane; Dipyridamole; Ferrous Compounds; Humans; Kinetics; Lipid Peroxidation; Liver; Malondialdehyde; Mopidamol; Pyrimidines; Rats; Species Specificity; Vitamin E | 1992 |
Does the association dipyridamole-aspirin only act by a functional synergism?
Topics: Aspirin; Blood Platelets; Dipyridamole; Drug Combinations; Drug Synergism; Humans; In Vitro Techniques; Malondialdehyde; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors | 1991 |
Exhausted platelets in chronic obstructive pulmonary disease.
Topics: Aged; beta-Thromboglobulin; Blood Platelets; Dipyridamole; Female; Humans; Lung Diseases, Obstructive; Male; Malondialdehyde; Middle Aged | 1983 |
Pharmacological control of platelet-vessel wall interactions in patients with chronic obstructive airway disease.
Topics: Aspirin; Blood Platelets; Blood Vessels; Dipyridamole; Hematopoiesis; Humans; Lung Diseases, Obstructive; Malondialdehyde; Pulmonary Embolism | 1984 |
Influence of the pure synthetic PAF (platelet aggregating factor) on clot retraction and platelet aggregation.
Topics: Animals; Blood Physiological Phenomena; Clot Retraction; Depression, Chemical; Dipyridamole; Dose-Response Relationship, Drug; Humans; Isotonic Solutions; Malondialdehyde; Platelet Activating Factor; Platelet Aggregation; Rats; Verapamil | 1984 |
[Stimulation of prostacyclin biosynthesis as a possible mechanism of action of dipyridamole (author's transl)].
Topics: Animals; Arachidonic Acids; Dipyridamole; Epoprostenol; Guinea Pigs; Heart; Lung; Malondialdehyde; Microsomes; Myocardium; Prostaglandins; Rabbits; Rats; Swine; Thromboxane A2 | 1981 |
Dipyridamole treatment in chronic obstructive airways disease: effect on platelet regeneration time.
Topics: Adult; Blood Gas Analysis; Blood Platelets; Dipyridamole; Humans; Lung Diseases, Obstructive; Male; Malondialdehyde; Time Factors | 1982 |
A comparative study on the effect of dilazep and dipyridamole on some platelet functions.
Topics: Adult; Aged; Azepines; Dilazep; Dipyridamole; Female; Fibrinogen; Humans; Male; Malondialdehyde; Middle Aged; Partial Thromboplastin Time; Platelet Aggregation; Platelet Count; Prothrombin Time; Time Factors | 1982 |
Heparin-induced thrombocytopenia: effect of heparin platelet antibody on platelets.
Topics: Adenosine Diphosphate; Adult; Antibodies; Aspirin; Blood Platelets; Complement Fixation Tests; Dipyridamole; Female; Heparin; Humans; Indomethacin; Male; Malondialdehyde; Middle Aged; Platelet Aggregation; Platelet Factor 3; Thrombocytopenia; Thromboxane B2 | 1981 |
A potent chain-breaking antioxidant activity of the cardiovascular drug dipyridamole.
Topics: Antioxidants; Arachidonic Acid; Dipyridamole; Free Radicals; Kinetics; Linoleic Acids; Lipid Peroxidation; Malondialdehyde; Micelles; Peroxides; Solvents; Vitamin E | 1995 |
The pyrimido-pyrimidine derivatives, dipyridamole and RA-642, reduce opacification of crystalline lens in diabetic rats.
Topics: Animals; Blood Glucose; Cardiotonic Agents; Cataract; Diabetes Mellitus, Experimental; Dipyridamole; Lens, Crystalline; Lipid Peroxidation; Male; Malondialdehyde; Mopidamol; Pyrimidines; Rats; Rats, Wistar; Superoxides | 1994 |
Inhibition of ferrous-induced lipid peroxidation by dipyridamole, RA-642 and mopidamol in human lung tissue.
Topics: Adult; Aged; Animals; Antioxidants; Dipyridamole; Female; Ferrous Compounds; Humans; In Vitro Techniques; Lipid Peroxidation; Lung; Male; Malondialdehyde; Middle Aged; Mopidamol; Pyrimidines; Rats; Rats, Wistar; Thiobarbituric Acid Reactive Substances; Vitamin E | 1996 |
Therapeutic effect of a newly developed antioxidative agent (OPC-15161) on experimental immune complex nephritis.
Topics: Animals; Antioxidants; Dipyridamole; Free Radical Scavengers; Immune Complex Diseases; Kidney; Kidney Cortex; Lipid Peroxidation; Male; Malondialdehyde; Nephritis; Phosphatidylcholines; Prednisolone; Proteinuria; Pyrazines; Rats; Rats, Sprague-Dawley; Superoxide Dismutase; Superoxides | 1997 |
Treatment of glomerular endothelial dysfunction in steroid-resistant nephrosis with Ganoderma lucidum, vitamins C, E and vasodilators.
Topics: Adrenal Cortex Hormones; Angiotensin II; Ascorbic Acid; Calcium Channel Blockers; Dipyridamole; Drug Evaluation; Drug Resistance; Drug Therapy, Combination; Enalapril; Endothelial Cells; Glutathione; Humans; Kidney Function Tests; Kidney Glomerulus; Malondialdehyde; Nephrosis; Oxidative Stress; Phytotherapy; Plants, Medicinal; Platelet Aggregation Inhibitors; Proteinuria; Reishi; Renal Circulation; Treatment Outcome; Vasodilator Agents; Vitamin E | 2003 |
Dipyridamole ameliorates doxorubicin-induced cardiotoxicity.
Topics: Animals; Antioxidants; Apoptosis; Biomarkers; Cardiotoxicity; Dipyridamole; Doxorubicin; Interleukin-6; Male; Malondialdehyde; Myocardium; Rats; Rats, Wistar; Saline Solution; Tumor Necrosis Factor-alpha | 2022 |